Sun Pharmaceutical Industries
Market Cap
₹959.0b
Last Updated
2019/10/17 12:47 UTC
Data Sources
Company Financials +
Executive Summary
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally.
Snowflake
Fundamentals
Excellent balance sheet average dividend payer.
Similar Companies
Share Price & News
How has Sun Pharmaceutical Industries's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
3.7%
SUNPHARMA
1.4%
IN Pharmaceuticals
1.4%
IN Market
1 Year Return
-32.3%
SUNPHARMA
-20.0%
IN Pharmaceuticals
2.3%
IN Market
Return vs Industry: SUNPHARMA underperformed the Indian Pharmaceuticals industry which returned -20% over the past year.
Return vs Market: SUNPHARMA underperformed the Indian Market which returned 2.3% over the past year.
Shareholder returns
| SUNPHARMA | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.7% | 1.4% | 1.4% |
| 30 Day | -4.6% | -7.1% | 2.7% |
| 90 Day | -4.7% | -5.2% | -1.4% |
| 1 Year | -31.9%-32.3% | -19.3%-20.0% | 4.3%2.3% |
| 3 Year | -45.3%-46.1% | -27.3%-28.8% | 20.9%14.9% |
| 5 Year | -49.4%-50.4% | -11.9%-14.6% | 41.2%28.2% |
Price Volatility Vs. Market
How volatile is Sun Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?
Simply Wall St News
11 months ago | Simply Wall St
Is Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) 9.6% ROE Strong Compared To Its Industry?1 year ago | Simply Wall St
Who Are The Major Shareholders In Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)?1 year ago | Simply Wall St
Is Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Attractive At Its Current PE Ratio?Valuation
Is Sun Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
32.17x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: SUNPHARMA (₹401.5) is trading above our estimate of fair value (₹262.13)
Significantly Undervalued: SUNPHARMA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SUNPHARMA is poor value based on its PE Ratio (32.2x) compared to the Pharmaceuticals industry average (15.6x).
PE vs Market: SUNPHARMA is poor value based on its PE Ratio (32.2x) compared to the Indian market (13x).
Price to Earnings Growth Ratio
Low PEG Ratio: SUNPHARMA is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: SUNPHARMA is overvalued based on its PB Ratio (2.3x) compared to the IN Pharmaceuticals industry average (1.5x).
Next Steps
Future Growth
How is Sun Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 27 analysts?
17.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SUNPHARMA's forecast earnings growth (17.4% per year) is above the savings rate (7.6%).
Earnings vs Market: SUNPHARMA's earnings (17.4% per year) are forecast to grow slower than the Indian market (18.1% per year).
High Growth Earnings: SUNPHARMA's earnings are forecast to grow, but not significantly.
Revenue vs Market: SUNPHARMA's revenue (9.8% per year) is forecast to grow slower than the Indian market (11.4% per year).
High Growth Revenue: SUNPHARMA's revenue (9.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: SUNPHARMA's Return on Equity is forecast to be low in 3 years time (11.4%).
Next Steps
Past Performance
How has Sun Pharmaceutical Industries performed over the past 5 years?
-13.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: SUNPHARMA's earnings have declined by -13.4% per year over the past 5 years.
Accelerating Growth: SUNPHARMA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SUNPHARMA had negative earnings growth (-16.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.4%).
Return on Equity
High ROE: SUNPHARMA's Return on Equity (7.9%) is considered low.
Return on Assets
ROA vs Industry: SUNPHARMA's Return on Assets is below or equal to the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: SUNPHARMA's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Sun Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: SUNPHARMA's short term assets (₹310.7B) exceeds its short term liabilities (₹173.4B)
Long Term Liabilities: SUNPHARMA's short term assets (310.7B) exceeds its long term liabilities (26.3B)
Debt to Equity History and Analysis
Debt Level: SUNPHARMA's debt to equity ratio (23.2%) is considered satisfactory
Reducing Debt: SUNPHARMA's debt to equity ratio has increased from 12.4% to 23.2% over the past 5 years.
Debt Coverage: SUNPHARMA's debt is well covered by operating cash flow (21.2%).
Interest Coverage: SUNPHARMA earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: SUNPHARMA has a high level of physical assets or inventory.
Debt Coverage by Assets: SUNPHARMA's debt is covered by short term assets (assets are 2.993250x debt).
Next Steps
Dividend
What is Sun Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
0.68%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: SUNPHARMA's dividend (0.68%) is higher than the bottom 25% of dividend payers in the Indian market (0.61%).
High Dividend: SUNPHARMA's dividend (0.68%) is low compared to the top 25% of dividend payers in the Indian market (2.51%).
Stable Dividend: SUNPHARMA's dividend payments have been volatile in the past 10 years.
Growing Dividend: SUNPHARMA's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (22%), SUNPHARMA's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SUNPHARMA's dividends in 3 years are forecast to be thoroughly covered by earnings (13.9% payout ratio).
Next Steps
Management
What is the CEO of Sun Pharmaceutical Industries's salary, the management and board of directors tenure and is there insider trading?
2.7yrs
Average management tenure
CEO
Dilip Shanghvi (64yo)
0yrs
Tenure
₹262,801
Compensation
Mr. Dilip Shantilal Shanghvi has been the Chairman and Managing Director of Sun Pharma Advanced Research Company Limited since March 1, 2012. Mr. Shanghvi Founded Sun Pharmaceutical Industries Limited in 1 ...
CEO Compensation Analysis
Compensation vs. Market: Dilip's total compensation ($USD3.68K) is too low to compare against companies of similar size in the Indian market ($USD997.50K).
Compensation vs Earnings: Dilip's compensation has been consistent with company performance over the past year.
Management Age and Tenure
2.7yrs
Average Tenure
64yo
Average Age
Experienced Management: SUNPHARMA's management team is considered experienced (2.7 years average tenure).
Board Age and Tenure
6.5yrs
Average Tenure
64.5yo
Average Age
Experienced Board: SUNPHARMA's board of directors are considered experienced (6.5 years average tenure).
Insider Trading
Insider Buying: SUNPHARMA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 500,000 |
| Max Price | ₹404.79 |
| Entity | Company |
| Shares | 200,000 |
| Max Price | ₹419.29 |
| Entity | Company |
| Shares | 400,000 |
| Max Price | ₹411.73 |
| Entity | Individual |
| Role | Member of the Board of Directors Whole Time Director |
| Shares | 8,000 |
| Max Price | ₹438.38 |
| Entity | Individual |
| Role | Member of the Board of Directors Whole Time Director |
| Shares | 13,000 |
| Max Price | ₹434.00 |
| Entity | Company |
| Shares | 400,000 |
| Max Price | ₹425.59 |
| Entity | Company |
| Shares | 1,000,000 |
| Max Price | ₹412.28 |
| Entity | Company |
| Shares | 1,400,000 |
| Max Price | ₹438.76 |
| Entity | Individual |
| Role | Member of the Board of Directors Whole Time Director |
| Shares | 57,000 |
| Max Price | ₹400.61 |
| Entity | Individual |
| Role | Member of the Board of Directors Whole Time Director |
| Shares | 150,000 |
| Max Price | ₹379.25 |
| Entity | Company |
| Shares | 50,000 |
| Max Price | ₹482.26 |
| Entity | Individual |
| Shares | 25,000 |
| Max Price | ₹479.02 |
| Entity | Company |
| Shares | 190,227 |
| Max Price | ₹479.80 |
| Entity | Company |
| Shares | 362,119 |
| Max Price | ₹472.34 |
| Entity | Individual |
| Shares | 377,881 |
| Max Price | ₹464.83 |
| Entity | Individual |
| Shares | 500,000 |
| Max Price | ₹470.91 |
| Entity | Individual |
| Shares | 6,000 |
| Max Price | ₹379.51 |
| Entity | Individual |
| Shares | 38,200 |
| Max Price | ₹425.25 |
| Entity | Individual |
| Shares | 7,772 |
| Max Price | ₹510.00 |
| Entity | Individual |
| Shares | 5,500 |
| Max Price | ₹491.75 |
| Entity | Individual |
| Shares | 3,000 |
| Max Price | ₹486.02 |
| Entity | Individual |
| Shares | 3,000 |
| Max Price | ₹525.17 |
| Entity | Individual |
| Shares | 15,000 |
| Max Price | ₹574.65 |
Ownership Breakdown
Management Team
Dilip Shanghvi (64yo)
MD & Executive Director
- Tenure: 0yrs
- Compensation: ₹262.80k
Sailesh Desai (65yo)
Whole Time Director
- Tenure: 20.6yrs
- Compensation: ₹14.23m
Arun Sawhney (64yo)
President
- Tenure: 0yrs
Kal Subramanian (65yo)
CEO of India Business and Emerging Markets & Whole-Time Director
- Tenure: 2.7yrs
Indrajit Banerjee (63yo)
President
- Tenure: 0yrs
C. Muralidharan (56yo)
Chief Financial Officer
- Tenure: 2.3yrs
- Compensation: ₹3.28m
Sunil Ajmera
Company Secretary
- Tenure: 8.5yrs
- Compensation: ₹1.37m
Govind Jaju
President and Global Head of Technical Operations
- Tenure: 0yrs
Davinder Singh
Senior Vice-President of Sun Pharmaceutical Global Operations
- Tenure: 0yrs
Atanu Roy
Senior VP & Chief Information Officer
- Tenure: 0yrs
Board Members
Israel Makov (80yo)
Chairman of the Board
- Tenure: 7.4yrs
- Compensation: ₹900.00k
Dilip Shanghvi (64yo)
MD & Executive Director
- Tenure: 0yrs
- Compensation: ₹262.80k
Sudhir Valia (63yo)
Non-Executive & Non-Independent Director
- Tenure: 14.7yrs
- Compensation: ₹79.20k
Sailesh Desai (65yo)
Whole Time Director
- Tenure: 20.6yrs
- Compensation: ₹14.23m
Gautam Doshi (66yo)
Non-Executive Independent Director
- Tenure: 1.4yrs
- Compensation: ₹1.30m
Kal Subramanian (65yo)
CEO of India Business and Emerging Markets & Whole-Time Director
- Tenure: 2.7yrs
Vivek Sehgal (63yo)
Additional Independent Director
- Tenure: 1.9yrs
- Compensation: ₹600.00k
Rekha Sethi (56yo)
Non-Executive Independent Director
- Tenure: 5.7yrs
- Compensation: ₹1.50m
Company Information
Sun Pharmaceutical Industries Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sun Pharmaceutical Industries Limited
- Ticker: SUNPHARMA
- Exchange: NSEI
- Founded: 1983
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹959.014b
- Shares outstanding: 2.40b
- Website: https://www.sunpharma.com
Number of Employees
Location
- Sun Pharmaceutical Industries Limited
- Sun House
- Plot No. 201 B/1
- Mumbai
- Maharashtra
- 400063
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 524715 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Feb 1995 |
| SUNPHARMA | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Feb 1995 |
Biography
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and inter ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/17 12:47 |
| End of Day Share Price | 2019/10/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.